This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

XCHC Announces Initial Planning And Development Of Cannabis Medical Treatment Centers To Open In Colorado, California, And Other Friendly Markets Across The Globe

Stocks in this article: XCHC

DALLAS, March 6, 2013 /PRNewswire/ -- X-Change Corp. (NASDAQ OTC: XCHC), a U.S. Company specializing in cannabinoid formulation-based health solutions through its Phytiva brand product lines announces, plans to develop and open cannabis medical treatment centers in Colorado, California, and other U.S. and international markets where existing law permits. 

X-Change Corporation is proud to announce the commencement of plans to facilitate the opening of its first treatment center in Colorado.  The paramount focus of this clinic will be treating several different types of cancer but will address other ailments as well.  The Company is in the process of recruiting in-house experts for clinics and organic research consistent with Colorado's new legal framework.

In addition to the servicing of people with these ailments, the Company plans for this medical center to collect vital data with regard to objective and scientifically based analysis of the progress of patients that can be used to further develop the Company's formulations and treatment protocols. 

X-Change Corp's focus will be on its strategic alliances in Colorado, California, and states where the Company can participate in the initiation of operations and conduct business in full legal compliance with like-minded partners that have been issued the legal authority from their local jurisdictions to commence these important treatment activities.   Simultaneously, the Company's broader goal is to focus on other countries that are friendly to similar business models, such as Canada, Germany, and other European markets, before moving into Asian and Latin American markets in the mid and long term.

The Company is proud to be working with a wide range of master growers and entrepreneurs who support the mission of meeting the needs of their communities with products based on proven cannabinoid science, as well as of advocating for patient rights throughout the world.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs